Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet

被引：12

作者：

Schneider, U

Ruhnke, M

Delecluse, HJ

Stein, H

Huhn, D

机构：

[1] Humboldt Univ, Charite, Dept Med, Div Hematol Oncol, D-13353 Berlin, Germany

[2] GSF Munich, Inst Klin Mol Biol Haematologikum, D-81377 Munich, Germany

[3] Univ Berlin, Klinikum Benjamin Franklin, Inst Pathol, D-12200 Berlin, Germany

来源：

ANNALS OF HEMATOLOGY | 2000年 / 79卷 / 04期

关键词：

EBV-associated lymphoproliferative disorders AIDS; foscarnet;

D O I：

10.1007/s002770050581

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Epstein-Barr virus (EBV)-associated lymphoproliferative disorders frequently develop in patients with acquired immunodeficiency syndrome (AIDS). The lymphoproliferative disorders are usually treated with a combination of cytotoxic drugs, and virustatic medication is thought to be ineffective. However, we report about two AIDS patients with EBV-associated lymphoproliferative disorders not responding to a standard chemotherapy, who achieved complete tumour regression after virustatic therapy with foscarnet.

引用

页码：214 / 216

页数：3

共 10 条

[1]

DELECLUSE HJ, 1993, BLOOD, V82, P552

[2]

HAMILTONDUTOIT SJ, 1991, AM J PATHOL, V138, P149

[3]

HAMILTONDUTOIT SJ, 1993, BLOOD, V82, P619

[4] INDUCTION OF BCL-2 EXPRESSION BY EPSTEIN-BARR-VIRUS LATENT MEMBRANE PROTEIN-1 PROTECTS INFECTED B-CELLS FROM PROGRAMMED CELL-DEATH [J].